Anthony T. Reder to Natalizumab
This is a "connection" page, showing publications Anthony T. Reder has written about Natalizumab.
Connection Strength
0.391
-
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
Score: 0.199
-
Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. PLoS One. 2018; 13(12):e0209326.
Score: 0.171
-
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology. 2008 Jul 08; 71(2):136-44.
Score: 0.021